Melfalan Teva

Melphalan, the active ingredient in Melfalan Teva, is a Alkylating agent presented as a unknown/unknown for Intravenous use. It is used to treat certain cancers such as multiple myeloma, ovarian cancer, malignant melanoma and neuroblastoma. GNH USA supplies Melfalan Teva as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Melfalan Teva (melphalan) is an alkylating antineoplastic agent used in the treatment of several solid tumours and hematologic malignancies.

- Multiple myeloma: improves disease control and prolongs survival. - Ovarian cancer: incorporated into combination chemotherapy to reduce tumour burden. - Malignant melanoma: employed in high‑dose regimens for advanced disease. - Neuroblastoma: used in intensive protocols for high‑risk pediatric cases.

Adverse reactions to melphalan are common and can affect multiple organ systems.

Common Side Effects: - Nausea and vomiting. - Myelosuppression (decreased white blood cells, red blood cells, and platelets). - Alopecia (hair loss). - Fatigue. - Mucositis (inflammation of the mouth lining). - Diarrhoea.

Serious or Rare Side Effects: - Severe neutropenia leading to infection. - Thrombocytopenia causing bleeding complications. - Pulmonary toxicity such as interstitial pneumonitis. - Secondary malignancies (e.g., therapy‑related leukaemia). - Renal impairment. - Cardiac arrhythmias.

When using melphalan, careful monitoring and patient education are essential to minimise risks. - Blood counts: monitor complete blood count regularly to detect myelosuppression. - Renal function: assess serum creatinine and adjust therapy if needed. - Pulmonary status: evaluate for signs of respiratory distress or pneumonitis. - Hypersensitivity: discontinue if an allergic reaction occurs. - Contraception: advise both male and female patients to use effective contraception during treatment and for a defined period after. - Store at ambient temperature: keep in original container, protect from light and moisture.

Melphalan may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other alkylating agents (increased toxicity). - High‑dose radiation therapy (enhanced tissue damage). - Live vaccines (risk of infection due to immunosuppression). - Strong CYP450 inducers (may reduce plasma levels, though melphalan is not primarily metabolised by CYP enzymes).

Moderate Interactions (Monitor Closely): - Anticoagulants (enhanced bleeding risk). - Nephrotoxic drugs such as aminoglycosides (potential renal impairment). - Immunosuppressants (additive suppression of bone marrow).